Lung Cancer Clinical Trial

Clinical Trial Finder Lung Cancer Trials

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

See Locations Near You

Summary

BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled:

Cohort I: Patients previously treated with one taxane containing regimen.
Cohort II: Patients previously treated with a platinum based but non-taxane containing regimen.
Cohort III: Patients previously treated with both a chemotherapy regimen and one EGFR-TKI (epidermal growth factor receptor-tyrosine kinase inhibitor) compound.

Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound. Prior treatment with a VEGFR (vascular endothelial growth factor receptor) inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Men and women, age >= 18 years
Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC who failed only one prior chemotherapy regimen.

Exclusion Criteria:

Concomitant medication with a cytochrome P450 (CYP) 3A4 inhibitor or inducer

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

186

Study ID:

NCT00359450

Recruitment Status:

Terminated

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Local Institution
Burlington Massachusetts, , United States
Local Institution
St. Louis Missouri, , United States
Local Institution
Morganton North Carolina, , United States
Local Institution
Cleveland Ohio, , United States
Local Institution
Charleroi , , Belgium
Local Institution
Leuven , , Belgium
Local Institution
Montreal Ontario, , Canada
Local Institution
Thunder Bay Ontario, , Canada
Local Institution
Toronto Ontario, , Canada
Local Institution
St. Jerome Quebec, , Canada
Local Institution
Belfort , , France
Local Institution
Besancon , , France
Local Institution
Poitiers , , France
Local Institution
Saint-Herblain Cedex , , France
Local Institution
Strasbourg , , France
Local Institution
Tours , , France
Local Institution
Napoli , , Italy
Local Institution
Orbassano Torino , , Italy
Local Institution
Perugia , , Italy
Local Institution
Roma , , Italy
Local Institution
Amsterdam , , Netherlands
Local Institution
Maastricht , , Netherlands
Local Institution
Barcelona , , Spain
Local Institution
Madrid , , Spain
Local Institution
Cambridge Cambridgeshire, , United Kingdom
Local Institution
Glasgow Central, , United Kingdom
Local Institution
Plymouth Devon, , United Kingdom
Local Institution
London Greater London, , United Kingdom
Local Institution
Northwood Middlesex, , United Kingdom
Local Institution
Oxford Oxfordshire, , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 2

Estimated Enrollment:

186

Study ID:

NCT00359450

Recruitment Status:

Terminated

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
When Should I Consider Clinical Trials?
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider